Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Malignancies.

Varughese T, Taur Y, Cohen N, Palomba ML, Seo SK, Hohl TM, Redelman-Sidi G.

Clin Infect Dis. 2018 Mar 2. doi: 10.1093/cid/ciy175. [Epub ahead of print]

PMID:
29509845
2.

A Phase I Study of Ibrutinib in Combination with R-ICE in Patients with Relapsed or Primary Refractory DLBCL.

Sauter CS, Matasar MJ, Schoder H, Devlin SM, Drullinsky P, Gerecitano J, Kumar A, Noy A, Palomba ML, Portlock CS, Straus DJ, Zelenetz AD, McCall SJ, Miller ST, Courtien AI, Younes A, Moskowitz CH.

Blood. 2018 Jan 31. pii: blood-2017-08-802561. doi: 10.1182/blood-2017-08-802561. [Epub ahead of print]

PMID:
29386196
3.

Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.

Moskowitz AJ, Schöder H, Gavane S, Thoren KL, Fleisher M, Yahalom J, McCall SJ, Cadzin BR, Fox SY, Gerecitano J, Grewal R, Hamlin PA, Horwitz SM, Kumar A, Matasar M, Ni A, Noy A, Palomba ML, Perales MA, Portlock CS, Sauter C, Straus D, Younes A, Zelenetz AD, Moskowitz CH.

Blood. 2017 Nov 16;130(20):2196-2203. doi: 10.1182/blood-2017-06-788877. Epub 2017 Sep 5.

PMID:
28874350
4.

Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.

Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, Codega P, Nichol D, Clark O, Hsieh WY, Rohle D, Rosenblum M, Viale A, Tabar VS, Brennan CW, Gavrilovic IT, Kaley TJ, Nolan CP, Omuro A, Pentsova E, Thomas AA, Tsyvkin E, Noy A, Palomba ML, Hamlin P, Sauter CS, Moskowitz CH, Wolfe J, Dogan A, Won M, Glass J, Peak S, Lallana EC, Hatzoglou V, Reiner AS, Gutin PH, Huse JT, Panageas KS, Graeber TG, Schultz N, DeAngelis LM, Mellinghoff IK.

Cancer Discov. 2017 Sep;7(9):1018-1029. doi: 10.1158/2159-8290.CD-17-0613. Epub 2017 Jun 15.

PMID:
28619981
5.

The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.

Soumerai JD, Zelenetz AD, Moskowitz CH, Palomba ML, Hamlin PA Jr, Noy A, Straus DJ, Moskowitz AJ, Younes A, Matasar MJ, Horwitz SM, Portlock CS, Konner JA, Gounder MM, Hyman DM, Voss MH, Fury MG, Gajria D, Carvajal RD, Ho AL, Beumer JH, Kiesel B, Zhang Z, Chen A, Little RF, Jarjies C, Dang TO, France F, Mishra N, Gerecitano JF.

Clin Cancer Res. 2017 Aug 1;23(15):4119-4126. doi: 10.1158/1078-0432.CCR-16-3068. Epub 2017 Mar 17.

6.
7.

Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia.

Xu L, Tsakmaklis N, Yang G, Chen JG, Liu X, Demos M, Kofides A, Patterson CJ, Meid K, Gustine J, Dubeau T, Palomba ML, Advani R, Castillo JJ, Furman RR, Hunter ZR, Treon SP.

Blood. 2017 May 4;129(18):2519-2525. doi: 10.1182/blood-2017-01-761726. Epub 2017 Feb 24.

PMID:
28235842
8.

Future therapeutic options for patients with Waldenström macroglobulinemia.

Castillo JJ, Hunter ZR, Yang G, Argyropoulos K, Palomba ML, Treon SP.

Best Pract Res Clin Haematol. 2016 Jun;29(2):206-215. doi: 10.1016/j.beha.2016.08.021. Epub 2016 Sep 14. Review.

PMID:
27825467
9.

Learning from Waldenstrom Macroglobulinemia.

Palomba ML.

Best Pract Res Clin Haematol. 2016 Jun;29(2):135. doi: 10.1016/j.beha.2016.09.001. Epub 2016 Oct 5. No abstract available.

PMID:
27825458
10.

Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience.

Castillo JJ, Palomba ML, Advani R, Treon SP.

Ther Adv Hematol. 2016 Aug;7(4):179-86. doi: 10.1177/2040620716654102. Epub 2016 Jun 13. Review.

11.

Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.

Kumar A, Casulo C, Yahalom J, Schöder H, Barr PM, Caron P, Chiu A, Constine LS, Drullinsky P, Friedberg JW, Gerecitano JF, Hamilton A, Hamlin PA, Horwitz SM, Jacob AG, Matasar MJ, McArthur GN, McCall SJ, Moskowitz AJ, Noy A, Palomba ML, Portlock CS, Straus DJ, VanderEls N, Verwys SL, Yang J, Younes A, Zelenetz AD, Zhang Z, Moskowitz CH.

Blood. 2016 Sep 15;128(11):1458-64. doi: 10.1182/blood-2016-03-703470. Epub 2016 Jul 25.

12.

Clonal B cells in Waldenström's macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling.

Argyropoulos KV, Vogel R, Ziegler C, Altan-Bonnet G, Velardi E, Calafiore M, Dogan A, Arcila M, Patel M, Knapp K, Mallek C, Hunter ZR, Treon SP, van den Brink MR, Palomba ML.

Leukemia. 2016 May;30(5):1116-25. doi: 10.1038/leu.2016.8. Epub 2016 Feb 12.

13.

A Positive Prospective Trial of Antibiotic Therapy in Advanced Stage, Non-Bulky Indolent Lymphoma.

Portlock CS, Hamlin PA, Gerecitano JF, Noy A, Palomba ML, Walkley J, Corcoran S, Migliacci J, Schoder H, Papanicolaou G, Markowitz AJ.

Tumor Microenviron Ther. 2015 Feb;2(1):14-18. Epub 2015 Feb 18.

14.

Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study.

Castillo JJ, D'Sa S, Lunn MP, Minnema MC, Tedeschi A, Lansigan F, Palomba ML, Varettoni M, Garcia-Sanz R, Nayak L, Lee EQ, Rinne ML, Norden AD, Ghobrial IM, Treon SP.

Br J Haematol. 2016 Mar;172(5):709-15. doi: 10.1111/bjh.13883. Epub 2015 Dec 21.

15.

West Nile Virus Central Nervous System Infection in Patients Treated With Rituximab: Implications for Diagnosis and Prognosis, With a Review of Literature.

Morjaria S, Arguello E, Taur Y, Sepkowitz K, Hatzoglou V, Nemade A, Rosenblum M, Cavalcanti MS, Palomba ML, Kaltsas A.

Open Forum Infect Dis. 2015 Sep 19;2(4):ofv136. doi: 10.1093/ofid/ofv136. eCollection 2015 Dec.

16.

Ibrutinib in previously treated Waldenström's macroglobulinemia.

Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, Argyropoulos KV, Yang G, Cao Y, Xu L, Patterson CJ, Rodig S, Zehnder JL, Aster JC, Harris NL, Kanan S, Ghobrial I, Castillo JJ, Laubach JP, Hunter ZR, Salman Z, Li J, Cheng M, Clow F, Graef T, Palomba ML, Advani RH.

N Engl J Med. 2015 Apr 9;372(15):1430-40. doi: 10.1056/NEJMoa1501548.

17.

PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.

Moskowitz AJ, Schöder H, Yahalom J, McCall SJ, Fox SY, Gerecitano J, Grewal R, Hamlin PA, Horwitz S, Kobos R, Kumar A, Matasar M, Noy A, Palomba ML, Perales MA, Portlock CS, Sauter C, Shukla N, Steinherz P, Straus D, Trippett T, Younes A, Zelenetz A, Moskowitz CH.

Lancet Oncol. 2015 Mar;16(3):284-92. doi: 10.1016/S1470-2045(15)70013-6. Epub 2015 Feb 13.

PMID:
25683846
18.

Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis.

Schatz JH, Horwitz SM, Teruya-Feldstein J, Lunning MA, Viale A, Huberman K, Socci ND, Lailler N, Heguy A, Dolgalev I, Migliacci JC, Pirun M, Palomba ML, Weinstock DM, Wendel HG.

Leukemia. 2015 Jan;29(1):237-41. doi: 10.1038/leu.2014.261. Epub 2014 Sep 3. No abstract available.

19.

Multidimensional single-cell analysis of BCR signaling reveals proximal activation defect as a hallmark of chronic lymphocytic leukemia B cells.

Palomba ML, Piersanti K, Ziegler CG, Decker H, Cotari JW, Bantilan K, Rijo I, Gardner JR, Heaney M, Bemis D, Balderas R, Malek SN, Seymour E, Zelenetz AD, van den Brink MR, Altan-Bonnet G.

PLoS One. 2014 Jan 29;9(1):e79987. doi: 10.1371/journal.pone.0079987. eCollection 2014.

20.

In the spotlight: a novel CD37 antibody-drug conjugate.

Palomba ML, Younes A.

Blood. 2013 Nov 14;122(20):3397-8. doi: 10.1182/blood-2013-09-526384.

21.

Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity.

Ghosh A, Dogan Y, Moroz M, Holland AM, Yim NL, Rao UK, Young LF, Tannenbaum D, Masih D, Velardi E, Tsai JJ, Jenq RR, Penack O, Hanash AM, Smith OM, Piersanti K, Lezcano C, Murphy GF, Liu C, Palomba ML, Sauer MG, Sadelain M, Ponomarev V, van den Brink MR.

J Clin Invest. 2013 Jun;123(6):2654-62. doi: 10.1172/JCI66301. Epub 2013 May 15.

22.

Raynaud's phenomenon of the tongue.

Cohen JC, Palomba ML, Morris LG.

J Rheumatol. 2013 Mar;40(3):336. doi: 10.3899/jrheum.121093. No abstract available.

PMID:
23457400
23.

Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.

Moskowitz AJ, Hamlin PA Jr, Perales MA, Gerecitano J, Horwitz SM, Matasar MJ, Noy A, Palomba ML, Portlock CS, Straus DJ, Graustein T, Zelenetz AD, Moskowitz CH.

J Clin Oncol. 2013 Feb 1;31(4):456-60. doi: 10.1200/JCO.2012.45.3308. Epub 2012 Dec 17.

24.

Active immunotherapy: current state of the art in vaccine approaches for NHL.

Palomba ML.

Curr Oncol Rep. 2012 Oct;14(5):433-40. doi: 10.1007/s11912-012-0255-7. Review.

25.

Chemotherapy-related magnetic resonance imaging abnormalities mimicking disease progression following intraventricular liposomal cytarabine and high dose methotrexate for neurolymphomatosis.

Pentsova E, Rosenblum M, Holodny A, Palomba ML, Omuro A.

Leuk Lymphoma. 2012 Aug;53(8):1620-2. doi: 10.3109/10428194.2012.656632. Epub 2012 Feb 13. No abstract available.

PMID:
22242822
26.

Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.

Moskowitz CH, Schöder H, Teruya-Feldstein J, Sima C, Iasonos A, Portlock CS, Straus D, Noy A, Palomba ML, O'Connor OA, Horwitz S, Weaver SA, Meikle JL, Filippa DA, Caravelli JF, Hamlin PA, Zelenetz AD.

J Clin Oncol. 2010 Apr 10;28(11):1896-903. doi: 10.1200/JCO.2009.26.5942. Epub 2010 Mar 8.

27.

Life-threatening serotonin toxicity due to a citalopram-fluconazole drug interaction: case reports and discussion.

Levin TT, Cortes-Ladino A, Weiss M, Palomba ML.

Gen Hosp Psychiatry. 2008 Jul-Aug;30(4):372-7. doi: 10.1016/j.genhosppsych.2008.03.008. Review.

PMID:
18585543
28.

CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma.

Palomba ML, Roberts WK, Dao T, Manukian G, Guevara-Patiño JA, Wolchok JD, Scheinberg DA, Houghton AN.

Clin Cancer Res. 2005 Jan 1;11(1):370-9.

29.
30.

Psychological implications and acceptability of preimplantation diagnosis.

Palomba ML, Monni G, Lai R, Cau G, Olla G, Cao A.

Hum Reprod. 1994 Feb;9(2):360-2.

PMID:
8027297
31.

In situ localization of 3.2.3+ natural killer cells in tissues from normal and tumor-bearing rats.

van den Brink MR, Palomba ML, Basse PH, Hiserodt JC.

Cancer Res. 1991 Sep 15;51(18):4931-6.

Supplemental Content

Loading ...
Support Center